Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996528 | 1.00 | TSHR (0.44) | TSHRFDPSL3MBTL1ADRB2ADRB1 | |
| SCHEMBL278529 | 0.85 | L3MBTL1 (0.48) | TSHRFDPSL3MBTL1LMNATHRB | |
| SCHEMBL20099962 | 0.82 | TSHR (0.41) | TSHRFDPSL3MBTL1ADRB2ADRB1 | |
| SCHEMBL10192257 | 0.82 | FDPS (0.38) | TSHRFDPSL3MBTL1LMNATHRB | |
| SCHEMBL11189962 | 0.81 | — | — | |
| SCHEMBL34468064 | 0.81 | — | — | |
| SCHEMBL18231656 | 0.81 | — | — | |
| SCHEMBL20099935 | 0.80 | TSHR (0.42) | TSHRFDPSL3MBTL1ADRB2ADRB1 | |
| SCHEMBL19222041 | 0.79 | LMNA (0.36) | TSHRFDPSL3MBTL1ADRB2ADRB1 | |
| SCHEMBL10153324 | 0.79 | FDPS (0.36) | TSHRFDPSL3MBTL1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025104230-A1 | BENZOXAZOLES AS MODULATORS OF IL-17A | SANOFI (FR) | 2025-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | IL17A, IL2, IL36G | TSHR 3133/4885FDPS 573/4885L3MBTL1 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.